You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》海普瑞藥業(09989.HK)公開發售超購68倍 一手中籤率40%
阿思達克 07-07 09:15
已在深圳上市的海普瑞藥業(09989.HK)公布招股結果,發售價定於18.4元,為下限定價(招股價介乎18.4至20.6元),公開發售錄超購68.21倍,經重新分配後,公開發售股數增至40%。申請一手500股中籤率為40%。該公司將於明日(7月8日)在主板掛牌,由摩根士丹利及高盛擔任聯席保薦人。

五名基石投資者包括OrbiMed Funds、AVICT、歐萬達基金、3W及Anlan Funds已分別認購2,104.95萬股、1,262.95萬股、631.45萬股、420.95萬股及210.45萬股,合計4,630.75萬股佔緊隨全球發售完成後公司已發行股本約3.2%。

公司預計集資淨額為38.06億元,將主要用於償還現有債務以改善資本結構、於歐洲及其他市場發展營銷網絡及基建、提升研發生產能力,以及用於創新藥投資。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account